SCHEMBL4155490

SCHEMBL4155490

Cc1oncc1C(=O)N1CCC[C@H](c2nc(-c3cccs3)no2)C1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.72
ALDH1A1 P00352 4/20 0.71
LMNA P02545 3/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
HTT P42858 1/20 0.71
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
ATM Q13315 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
TSHR P16473 4/20 0.68
RAB9A P51151 3/20 0.67
NPC1 O15118 2/20 0.67
GAA P10253 2/20 0.65
MAPK1 P28482 2/20 0.65
POLB P06746 1/20 0.64
PKM P14618 2/20 0.64
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4155495 1.00 GRM5 (0.72) GRM5ALDH1A1LMNASMN1; SMN2HTT
SCHEMBL4152455 0.85 HSD11B1 (0.77) HSD11B1
SCHEMBL4152452 0.85 HSD11B1 (0.77) HSD11B1
SCHEMBL4133503 0.84 HSD11B1 (0.58) GRM5ALDH1A1LMNASMN1; SMN2HTT
SCHEMBL4133497 0.84 HSD11B1 (0.58) GRM5ALDH1A1LMNASMN1; SMN2HTT
SCHEMBL4151273 0.83 HSD11B1 (0.63) ALDH1A1LMNASMN1; SMN2HTTMEN1
SCHEMBL4151267 0.83 HSD11B1 (0.63) ALDH1A1LMNASMN1; SMN2HTTMEN1
SCHEMBL2030939 0.82 GRM5 (0.79) GRM5ALDH1A1LMNASMN1; SMN2HTT
SCHEMBL1974720 0.82 HSD11B1 (0.56) GRM5ALDH1A1LMNASMN1; SMN2HTT
SCHEMBL1970071 0.82 HSD11B1 (0.56) GRM5ALDH1A1LMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197897-A1 Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors ADDEX PHARMA SA (CH) 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197897-A1 Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors GRM5, GRM2, GRM3 GRM5 1/4885ALDH1A1 4047/4885LMNA 4756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.